CSTONE PHARMA-B(02616.HK): Proposes Open-Market Share Repurchase of Up to 136.45 Million Shares

NewTimeSpace News: CStone Pharmaceuticals (02616.HK) issued a voluntary announcement on May 13, 2026. Subject to the general mandate for share repurchase approved by shareholders at the annual general meeting held on June 25, 2025, and any future general mandate approved by shareholders (if applicable), the Company proposes to repurchase up to 136,450,133 shares on the open market from time to time.

The share repurchases will be conducted in compliance with the Listing Rules. The plan is expected to be launched after the Annual Meeting of the American Society of Clinical Oncology (ASCO). Updated clinical data of the Company’s core product CS2009, a PD-1/VEGF/CTLA-4 trispecific antibody, is scheduled to be presented at the ASCO Annual Meeting.

The Company stated that the timely implementation of the share repurchase plan fully reflects the confidence of the management and the Board in its R&D output, commercialisation progress and long-term growth prospects. It also underscores the Company’s commitment to enhancing shareholder returns and optimising the capital feedback mechanism.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.